Press release
Chikungunya market is expected to reach USD 1.4 billion by 2034
Chikungunya
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71953
Global spread is accelerating due to urbanization, climate change, and international travel, with outbreaks reported across Africa, Asia, Europe, and the Americas. The chikungunya market is growing due to advances in vaccine development, supportive antiviral research, and expansion of vector-control initiatives.
Market Overview
• Market Size (2024): USD 710 million
• Forecast (2034): USD 1.4 billion
• CAGR (2025-2034): 7.1%
Growth is driven by rising global incidence, strong vaccine R&D pipelines, and government-led disease surveillance and prevention programs.
Key Highlights:
• WHO classifies chikungunya as a re-emerging infectious disease with epidemic potential.
• No specific antiviral is approved; treatment remains supportive.
• Vaccines are in late-stage development, including Valneva's IXCHIQ (FDA approved in 2023).
• Rising global vector surveillance strengthening outbreak preparedness.
Segmentation Analysis
By Product Type:
• Vaccines
o IXCHIQ (Valneva - FDA approved 2023)
o Pipeline Vaccines (live-attenuated, virus-like particles, mRNA platforms)
• Therapeutics
o Analgesics & Antipyretics (paracetamol, NSAIDs)
o Corticosteroids (for chronic arthritis-like symptoms)
o Pipeline Antivirals (broad-spectrum antivirals under research)
• Diagnostics
o PCR-Based Molecular Testing
o Serological Tests (IgM, IgG ELISA)
o Rapid Point-of-Care Tests
• Vector Control Solutions
o Insecticides & Repellents
o Biological Control (Wolbachia-infected mosquitoes, genetic modification)
By Platform:
• Vaccines (virus-like particle, mRNA, live-attenuated)
• Small Molecules (NSAIDs, antivirals - pipeline)
• Diagnostics (PCR, serology, rapid kits)
• Vector Management
By Technology:
• Advanced Vaccine Platforms (VLP, mRNA, recombinant viral vectors)
• Molecular Diagnostics (RT-PCR, CRISPR-based emerging tools)
• AI-Driven Vector Surveillance
• Genetic Mosquito Control
By End Use:
• Hospitals & Clinics
• Diagnostic Laboratories
• Public Health Agencies
• Research Institutes
By Application:
• Acute Chikungunya Management
• Chronic/Post-Viral Arthritis Care
• Outbreak Surveillance & Prevention
• Clinical Research
Segmentation Summary:
Supportive care dominates today's management, but vaccines and antiviral pipelines represent the fastest-growing segments. Diagnostics and vector-control remain essential in outbreak control.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71953/chikungunya-market
Regional Analysis
North America
• ~34% share in 2024.
• FDA approval of Valneva's IXCHIQ boosting market growth.
• Strong government surveillance and vector control programs.
Europe
• ~27% share.
• EMA reviewing chikungunya vaccine approvals.
• Rising risk due to spread of Aedes albopictus.
Asia-Pacific
• Fastest-growing region with CAGR of ~8.2%.
• High endemic burden in India, Indonesia, and Southeast Asia.
• Expanding diagnostic and vaccination infrastructure.
Middle East & Africa
• High chikungunya prevalence in sub-Saharan Africa.
• Limited access to advanced vaccines and antivirals.
Latin America
• Brazil and Mexico driving regional outbreaks and demand for vaccination.
• Integration of vector control with dengue and Zika programs.
Regional Summary:
North America and Europe dominate due to vaccine development and regulatory approvals, while Asia-Pacific and Latin America remain high-burden growth markets due to recurring outbreaks.
Market Dynamics
Key Growth Drivers:
• Rising chikungunya incidence in tropical and subtropical regions.
• FDA approval of IXCHIQ (first licensed vaccine).
• Strong vaccine pipelines from multiple biotech firms.
• Expansion of AI-driven vector surveillance and genetic mosquito control.
Key Challenges:
• No specific antiviral treatments.
• High reliance on supportive care.
• Limited healthcare infrastructure in endemic low-income regions.
• Climate-driven mosquito spread complicating outbreak control.
Latest Trends:
• Rapid expansion of mRNA-based chikungunya vaccines.
• Integration of chikungunya vaccination with dengue and Zika programs.
• Global investment in CRISPR-based molecular diagnostics.
• Increasing use of Wolbachia-based and genetically engineered mosquitoes.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71953
Competitor Analysis
Major Players in the Market:
• Valneva SE (IXCHIQ - first approved vaccine)
• Emergent BioSolutions
• Moderna, Inc. (mRNA vaccine pipeline)
• Bharat Biotech (vaccine development)
• Takeda Pharmaceutical Company Ltd.
• GlaxoSmithKline plc
• Sanofi Pasteur
• Roche Holding AG (diagnostics)
• Abbott Laboratories (point-of-care kits)
• Thermo Fisher Scientific Inc. (PCR diagnostics)
Competitive Summary:
Valneva leads with IXCHIQ, while Moderna, Bharat Biotech, and Takeda explore vaccine pipelines. Abbott, Roche, and Thermo Fisher dominate diagnostics. Competition focuses on vaccine commercialization, diagnostic rollout, and integration of vector-control solutions.
Conclusion
The Chikungunya Market, valued at USD 710 million in 2024, is projected to reach USD 1.4 billion by 2034, growing at a CAGR of 7.1%. Vaccine approvals, diagnostic innovation, and integrated vector management will continue to drive growth.
Key Takeaways:
• Supportive care dominates today, but vaccines mark the biggest breakthrough.
• North America and Europe lead due to vaccine approvals, while Asia-Pacific grows fastest.
• AI-driven vector surveillance and mRNA vaccine platforms are reshaping the market.
• Future growth will come from prevention, rapid diagnostics, and global vaccination programs.
The next decade will transform chikungunya care from reactive outbreak response to proactive vaccination and precision vector management, creating strong opportunities for pharma, biotech, diagnostics, and public health innovators.
This report is also available in the following languages : Japanese (チクングニア市場), Korean (치쿤구냐 시장), Chinese (基孔肯雅市场), French (Marché du Chikungunya), German (Chikungunya-Markt), and Italian (Mercato Chikungunya), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71953/chikungunya-market#request-a-sample
Our More Reports:
Presbyopia Market
https://exactitudeconsultancy.com/reports/72311/presbyopia-market
Uveitis Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72310/uveitis-patient-pool-analysis-market
Autoimmune uveitis Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72309/autoimmune-uveitis-patient-pool-analysis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chikungunya market is expected to reach USD 1.4 billion by 2034 here
News-ID: 4180786 • Views: …
More Releases from Exactitude Consultancy
Cell Therapy Manufacturing Market to Reach USD 28.4 Billion by 2034, Growing at …
Introduction
Cell therapy has emerged as a transformative pillar of modern medicine, offering the potential to repair, replace, or regenerate damaged tissues and organs. From CAR-T cell therapies for oncology to stem cell therapies for regenerative medicine, the field is redefining treatment paradigms across oncology, neurology, cardiology, and rare diseases.
As clinical pipelines expand and more therapies achieve regulatory approval, demand for efficient and scalable cell therapy manufacturing has surged. Specialized technologies…
Despite safety concerns, adavosertib exhibits early antitumor activity in uterin …
Uterine serous carcinoma (USC) is a rare but highly aggressive subtype of endometrial cancer, accounting for less than 10% of endometrial cancer cases but contributing to a disproportionately high mortality rate. It is often diagnosed at advanced stages, making it difficult to treat with conventional methods.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72873
In recent years, the treatment landscape has expanded beyond chemotherapy and surgery to include targeted therapies,…
Market for Catheter-Related Bloodstream Infections: Overview, Therapies, and Imp …
Catheter-related bloodstream infections (CRBSIs) are among the most common and serious complications associated with intravascular catheters used in hospitals and long-term care settings. These infections can lead to prolonged hospital stays, increased healthcare costs, and higher mortality rates. With the rising use of central venous catheters, particularly among critically ill patients, oncology cases, and those requiring long-term intravenous therapy, the global demand for effective prevention and treatment solutions is growing…
ADC Technology Market to Reach USD 33.7 Billion by 2034, Growing at 13.2% CAGR
Introduction
Antibody-drug conjugates (ADCs) represent one of the most innovative breakthroughs in oncology, combining the target specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. By delivering highly toxic payloads directly to cancer cells, ADCs minimize systemic toxicity and enhance therapeutic efficacy.
As cancer incidence rises worldwide and the limitations of conventional chemotherapy become more evident, ADC technology is gaining momentum. With advancements in linker chemistry, payload design, and next-generation…
More Releases for Chikungunya
Chikungunya Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportu …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Projected Growth of the Chikungunya Market?
In recent times, there has been robust growth in the chikungunya market size. It is projected to expand from $0.59 billion in 2024 to $0.65 billion in 2025, with a compound annual growth rate (CAGR) of 9.8%. Factors that have contributed to this…
Chikungunya Pipeline Insight 2025: 10+ Advancing Therapies and Key Companies in …
The therapeutic landscape for Chikungunya, a viral disease transmitted by mosquitoes that causes severe joint pain, fever, and rash, is rapidly evolving, fueled by advancements in antiviral research and vaccine development. Leading biopharmaceutical companies such as Valneva, Moderna Therapeutics, Themis Bioscience, FIT Biotech, Bharat Biotech, and Emergex Vaccines are at the forefront of developing innovative therapies, targeting various stages of the virus lifecycle, immune modulation, and pain management to alleviate…
Chikungunya Fever Global Clinical Trials Review, H2, 2018: Researchmoz.us
Researchmoz added Most up-to-date research on "Chikungunya Fever Global Clinical Trials Review, H2, 2018" to its huge collection of research reports. An insight on the important factors and trends influencing the market.
Latest clinical trial report, Chikungunya Fever Global Clinical Trials Review, H2, 2018" provides an overview of Chikungunya Fever clinical trials scenario. This report provides top line data relating to the clinical trials on Chikungunya Fever. Report includes an overview…
Chikungunya Fever Market Segmentation 2018 with Recent Trend by 2023
Chikungunya Fever Market - Highlights
Chikungunya fever is a mosquito borne disease. The caU.S.Ative agent is a RNA virus that belongs to the alphavirus genus of the family Togaviridae. The transmission of the disease occurs from human to human by the bites of infected female mosquitoes. Most commonly, the mosquitoes involved are Aedes aegypti and Aedes albopictus. The symptoms of the disease includes muscle pain, headache, nausea, fatigue and rash.
There is…
Chikungunya Fever Market Worldwide Segmentation with Top Key Merchant – Avail …
Chikungunya Fever Market - Highlights
Chikungunya fever is a mosquito borne disease. The caU.S.Ative agent is a RNA virus that belongs to the alphavirus genus of the family Togaviridae. The transmission of the disease occurs from human to human by the bites of infected female mosquitoes. Most commonly, the mosquitoes involved are Aedes aegypti and Aedes albopictus. The symptoms of the disease includes muscle pain, headache, nausea, fatigue and rash.
There is…
Chikungunya Fever (Infectious Disease) Pipeline Forecast Report, H1, 2017 - Phar …
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chikungunya Fever Market- Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chikungunya Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press…
